News

Small Cap Stocks Lead the Way for OIS Index in September

Small Cap Stocks Lead the Way for OIS Index in September

By Michael Lachman | October 3, 2018

The OIS Index of ophthalmic stocks gave back some of its recent gains in September, declining by 4.1% against an overall flat market backdrop. The…

Read More
Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

By Steve Lenier | September 26, 2018

At OIS@ASRS 2016, Forrest Fleming, then CEO of TrueVision Systems, announced a new partnership with Alcon. He also introduced the result of that pairing: the…

Read More
Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

By Rich Kirkner | September 20, 2018

Netherlands-based Preceyes BV seems to have taken the lead in the race to develop a robotic platform for retinal surgery as it prepares to demonstrate…

Read More
MIGS Minus One: What’s Next?

MIGS Minus One: What’s Next?

By Michelle Dalton | September 12, 2018

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class…

Read More
OIS Index Follows the Stock Market Lower in December

Glaukos and STAAR Drive OIS Index into Record Territory

By Michael Lachman | September 12, 2018

The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index…

Read More
First US-Approved Nerve Growth Factor is for the Eye

First US-Approved Nerve Growth Factor is for the Eye

By Rich Kirkner | August 24, 2018

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to…

Read More
Novartis’ Plans for Brolucizumab and Beyond

Novartis’ Guerard Shares Plans for Brolucizumab, Lucentis, Gene Therapy, and FocalView App

By Rich Kirkner | August 22, 2018

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’…

Read More
Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

By Steve Lenier | August 15, 2018

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies…

Read More
OIS Index

OIS Index Lags Market Benchmarks in July

By Michael Lachman | August 8, 2018

The OIS Index of ophthalmic stocks declined by 1.1% in July, against a strong overall market backdrop. During the month, the overall US stock market…

Read More
Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

By Steve Lenier | August 8, 2018

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an…

Read More
A Future Vision of Medicine from the Masters of Retina

A Future Vision of Medicine from the Masters of Retina

By Rich Kirkner | August 2, 2018

Two forces are emerging in healthcare that could determine how quickly personalized medicine takes over: an outcomes-based system that pays drug makers only when their…

Read More
After Trial Results, Allergan Set to Tweak Abcipar Formulation

After Trial Results, Allergan Set to Tweak Abcipar Formulation

By Rich Kirkner | July 26, 2018

Last week, one day before the American Society of Retina Specialists and OIS Retina convened in Vancouver, Allergan and its collaborative partner Molecular Partners touted…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.